🇨🇭 Switzerland Country × Condition
quality of life Clinical Trials in Switzerland
Active clinical trials for quality of life with research sites in Switzerland. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 5 // Recruiting: 5 // Updated: Daily
Total Trials
5
Recruiting Now
5
Country
🇨🇭 Switzerland
Active Trials in Switzerland (5)
NCT02280889
Recruiting
Quality of Life and Stigmatization in Children With Congenital Melanocytic Nevi Before and After Nevus Excision
Enrollment
100 pts
Country
🇨🇭 Switzerland
University Children's Hospital, Zur...
View Trial → NCT06886841
Recruiting
Parental Well-being After Childbirth in Switzerland
Enrollment
4,200 pts
Country
🇨🇭 Switzerland
Laurent Gaucher
View Trial → NCT06443268
Recruiting
Cerebrovascular Disease: Quality of Life (CODE: QoL)
Enrollment
680 pts
Country
🇨🇭 Switzerland
University of Zurich
View Trial → NCT06377189
Recruiting
Psychiatric Consultation-Liaison Intervention in Primary Care: A Pilot Study
Enrollment
30 pts
Country
🇨🇭 Switzerland
Center for Primary Care and Public ...
View Trial → NCT05192876
Recruiting
Analysis of Outcomes and Adverse Events of Patients Undergoing Radiation Therapy
Enrollment
25,000 pts
Country
🇨🇭 Switzerland
Daniel Zwahlen
View Trial → Frequently Asked Questions
How many quality of life clinical trials are active in Switzerland?
There are currently 5 active clinical trials for quality of life with sites in Switzerland, of which 5 are actively recruiting patients.
How can I join a quality of life clinical trial in Switzerland?
To join a quality of life clinical trial in Switzerland, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in Switzerland directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are quality of life trials in Switzerland?
Active quality of life trials in Switzerland span multiple phases. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.